Part 1 will focus on the discovery workflow, and explore best practices for identifying and using new and legacy technologies to discover novel and functional drug candidates in an environment where speed and efficiency is now a mandate. The meeting will consider new approaches to the essential steps in the discovery process and how to make these more efficient by selectively and intelligently integrating the many new tools now available on the market. A key focus of the agenda will be a discussion of methods used to discover well-performing candidates and leads as early as possible – and to accomplish this goal at the lowest possible cost needed to achieve a high-quality outcome.

Preliminary Agenda

OPTIMIZING THE DISCOVERY WORKFLOW

Case Study: High Throughput Generation of Challenging Antigens

Medha Tomlinson, PhD, Principal Research Scientist, AbbVie

Meeting the Needs of Antibody Discovery and Engineering Campaigns with Automated Workflows

Avinash Gill, PhD, Senior Scientific Manager, Genentech

Applying Fully Automated Antibody Discovery Workflows for Finding the Needle in the Haystack

Stefan Zahn, PhD, Principal Scientist, Antibody Technology, Novo Nordisk AS, Denmark

PANEL DISCUSSION: Best Practices for Improving the Discovery Workflow

Avainash Gill, PhD, Senior Scientific Manager, Genentech (Moderator)

Stefan Zahn, PhD, Principal Scientist, Antibody Technology, Novo Nordisk AS, Denmark

Medha Tomlinson, PhD, Principal Research Scientist, AbbVie Bioresearch Center

SCREENING AND SELECTION

Best Practices for Evolving In-House Screening Libraries and Discovery Platforms

Andrew Nixon, PhD, Vice President, Biotherapeutics Molecule Discovery, Boehringer Ingelheim

Screening for Agonist Activity in Higher Valency Formats without the Need for Recombinant Material

Randall Brezski, PhD, Scientist, Antibody Engineering, Genentech

Building a Single Donor Phage Antibody Library with NGS Validation

Andrew Bradbury, PhD, MB BS (MD), CSO, Specifica, Inc.

PANEL DISCUSSION: Best Practices for Phenotypic and Functional Antibody Screening

Andrew Bradbury, PhD, MB BS, CSO, Specifica, Inc. (Moderator)

Randall Brezski, PhD, Scientist, Antibody Engineering, Genentech

Andrew Nixon, PhD, Vice President, Biotherapeutics Molecule Discovery, Boehringer Ingelheim

Sai Reddy, PhD, Assistant Professor, Biosystems Science and Engineering, ETH Zurich, Switzerland

IMPLEMENTING EMERGING DISCOVERY TECHNOLOGIES

High-Throughput Antibody Engineering in Mammalian Cells by CRISPR/Cas9-Mediated Homology-Directed Mutagenesis

Sai Reddy, PhD, Assistant Professor, Biosystems Science and Engineering, ETH Zurich, Switzerland

Engineering Cells at the Protein Level with Intracellular Antibodies

Andrea Marschall, PhD, Postdoctoral Researcher, Biochemistry, Brandeis University

Best Practices for Evaluation and Implementing New Technology Platforms

Shiv Krishnan, PhD, Head, Business Development & Licensing, Technology Platforms, Sanofi


Part 2: Discovery of Novel Cancer Immunotherapies

SEPTEMBER 27-28, 2018


The second part of the program will address the challenging circumstance of identifying novel approaches that can be used to enter the thriving immune-oncology space. The meeting will begin with a broad look at current understandings of the biology of immune-oncology and what has been learned from the many recent clinical studies in the space – and then explore specific opportunities related to new and underexplored targets, improvements in target selectivity and unmet medical needs. Special consideration will also be given to the translation of academic and clinical stage findings into commercial development programs. A discussion format will offer those in attendance a novel opportunity to explore strategies in this space with colleagues.

Preliminary Agenda

CURRENT STATUS AND FUTURE DIRECTIONS

KEYNOTE PRESENTATION: Diverse Biologics Modalities Underpin ‘Third Wave’ Cancer Immunology Therapeutics

Jonathon Sedgwick, PhD, Global Head, Cancer Immunology & Immune Modulation, Boehringer Ingelheim

Emerging Technologies for Personalizing Cancer Immunotherapy

Aaron Goldman, PhD, Instructor in Medicine, Harvard Medical School

OPPORTUNITIES IN NEW TARGET DISCOVERY

Microfluidic Single-Cell Technology in Immunology and Antibody Screening

Christoph Merten, PhD, Group Leader Microfluidics, European Molecular Biology Laboratory (EMBL), Germany

Antibody Discovery for Novel Multi-Targeting Strategy in Immuno-Oncology

Thomas Bouquin, PhD, Head, Biologics Research, Sanofi, France

Genome-Wide Networks of Stem Cell-Associated Retroviral Sequences Define Novel Diagnostic and Therapeutic Targets in Clinically Lethal Malignancies

Guennadi V. Glinskii, PhD, Research Scientist, Institute of Engineering in Medicine, University of California, San Diego

OPPORTUNITIES IN IMPROVED TARGETING AND SPECIFICITY

ErbB Targeted CAR-T Cell Immunotherapy of Head and Neck Cancer: T4 Immunotherapy

John Maher, PhD, Clinical Senior Lecturer in Immunology, Kings College London, United Kingdom

Development of DART® and TRIDENT™ Molecules to Target Costimulatory and Checkpoint Receptors for Immuno-Oncology Applications

Gundo Diedrich, PhD, Associate Director, MacroGenics

Converting PD-1 Refractory Tumors to Responders with Intratumoral Injection of a CpG-A TLR9 Agonist

Arthur M. Krieg, MD, CEO, Checkmate Pharmaceuticals

Peptide Based Checkpoint Inhibitor Binding to PD-1

Gabriel Gutierrez, PhD, Program Manager, Leidos Health

T-DM1-Resistant Cells Gain High Metastatic Potential: Identifying Novel Therapeutic Targets for the Treatment of T-DM1-Resistant Disease

Wen Jin Wu, MD, PhD, Senior Investigator, Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA

TRANSLATIONAL RESEARCH

Overcoming Specific Mechanisms of Resistance to Immuno-Oncology Therapies

Kris F. Sachsenmeier, PhD, Associate Director, Translational Sciences, AstraZeneca

Selection of Antibody-Drug Conjugate Targets Using Expression Data, Glycoproteomics, and Functional Screens

Jennifer J. Hill, PhD, Team Lead, MS & NMR Analytics, National Research Council Canada